Nocion Therapeutics key facts
as of Oct 2026- Developer of a small molecule charged sodium channel designed to treat the conditions arising from neurogenic inflammation.
- Nocion Therapeutics is valued at approximately $112.0M as of Oct 2026 (last reported valuation).
- It has raised $153.0M across 3 recorded rounds; the latest was Early Stage VC ($23.0M) in Dec 2025.
- Notable investors include RA Capital Management, F-Prime Capital, Eight Roads, Alexandria Venture Investments, Canaan Partners — 16 tracked in total.
- Nocion Therapeutics has filed 5 Form Ds with the SEC since 2021, most recently Mar 2026 ($23.0M sold to 13 investors).
- Status: Privately Held (backing).
Nocion Therapeutics's last reported valuation, Aug 2021. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch Nocion Therapeutics: the Monday email on marks, rounds and moves
Nocion Therapeutics funding rounds
3 roundsWho backs Nocion Therapeutics
16+Nocion Therapeutics valuation
Nocion Therapeutics's last reported valuation was $112 million in Aug 2021. No priced round, secondary trade or fund mark has surfaced since.
How much has Nocion Therapeutics raised?
Nocion Therapeutics has raised $153 million in total; 3 of its rounds are on record, from 2021 on. The largest on record was a $7 million Series A2 in Aug 2021; the most recent was a $23 million early-stage round in Dec 2025.
Nocion Therapeutics has filed 5 Form Ds with the SEC since 2021, most recently in Mar 2026 ($23 million sold to 13 investors).
Nocion Therapeutics investors
16 investors are on record for Nocion Therapeutics, including RA Capital Management, F-Prime Capital, Eight Roads and Alexandria Venture Investments. By type, the record holds 5 venture capital firms and 2 asset managers. The early-stage round in Dec 2025 drew 13 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: Arsenal Medical ($124 million), Stylus Medicine ($114 million) and Kernalbio ($111 million).
About Nocion Therapeutics
Developer of a small molecule charged sodium channel designed to treat the conditions arising from neurogenic inflammation. The company creates notions that target activated sensory neurons and enter activated nociceptors via large-pore channels on these neurons, enabling patients to gain relief through the treatment of serious conditions, including cough, itch, pain, and inflammation.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2017
- Employees
- 17
- Website
- nociontx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.